Bendamustine
- Generic Name
- Bendamustine
- Brand Names
- Belrapzo, Bendeka, Treanda, Vivimusta
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21Cl2N3O2
- CAS Number
- 16506-27-7
- Unique Ingredient Identifier
- 9266D9P3PQ
- Background
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...
- Indication
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
- Associated Therapies
- -
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2011-11-06
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 183
- Registration Number
- NCT01466153
- Locations
- 🇵🇱
Research Site, Warszawa, Poland
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2023-12-19
- Target Recruit Count
- 38
- Registration Number
- NCT01458366
- Locations
- 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 26
- Registration Number
- NCT01429025
- Locations
- 🇺🇸
Iowa Lutheran Hospital, Des Moines, Iowa, United States
🇺🇸Siouxland Hematology-Oncology, Sioux City, Iowa, United States
🇺🇸Iowa Oncology Research Association CCOP, Des Moines, Iowa, United States
A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)
- Conditions
- Interventions
- First Posted Date
- 2011-08-26
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT01423539
Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2011-08-25
- Last Posted Date
- 2011-08-25
- Lead Sponsor
- WiSP Wissenschaftlicher Service Pharma GmbH
- Target Recruit Count
- 96
- Registration Number
- NCT01423032
- Locations
- 🇩🇪
Prof. Dr. Norbert Niederle, Leverkusen, NRW, Germany
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-08-12
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 373
- Registration Number
- NCT01415752
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Mount Sinai Hospital Medical Center, Chicago, Illinois, United States
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
- First Posted Date
- 2011-08-09
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 53
- Registration Number
- NCT01412879
- Locations
- 🇺🇸
Illinois CancerCare - Galesburg, Galesburg, Illinois, United States
🇺🇸Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States
🇺🇸Wenatchee Valley Medical Center, Wenatchee, Washington, United States
A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-08-09
- Last Posted Date
- 2015-08-11
- Target Recruit Count
- 36
- Registration Number
- NCT01412307
- Locations
- 🇮🇹
Hematology Oncology and Stem Cell Transplantation Unit , IRCCS Fondazione "G.Pascale", Naples, Italy
Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL
- Conditions
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT01400685
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
- Conditions
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 60
- Registration Number
- NCT01376401
- Locations
- 🇪🇸
Hospital Universitario La Fe, Valencia, Spain
🇪🇸Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital Clínic, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.